patent.fyi
Applications  /  US 2026/0355144
United States Patent Application Publication

US 2026/0355144 A1

Published
Nov 12, 2026
Filed
Aug 10, 2023
Earliest date on the face
Aug 10, 2022
Classification
A61K 31/336
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Pirfenidone replaces MetAP2 inhibition

What ifWhat if the combination pairs nintedanib with pirfenidone and contains no MetAP2 inhibitor?
Claim language“at least one MetAP2 inhibitor”

Separate oral dosage forms deliver pirfenidone and nintedanib. Pirfenidone reduces transforming growth factor beta–stimulated collagen production in lung fibroblast models, while nintedanib inhibits receptor kinases involved in fibroblast proliferation.

1.1PDE4B inhibition replaces MetAP2 inhibition

What ifWhat if the combination pairs nintedanib with a preferential phosphodiesterase 4B inhibitor and contains no MetAP2 inhibitor?
Claim language“at least one MetAP2 inhibitor”

An oral nerandomilast tablet supplies preferential phosphodiesterase 4B inhibition. This reduces cyclic AMP breakdown and suppresses profibrotic cell responses, while nintedanib inhibits growth factor receptor signaling.

1.1Pirfenidone replaces nintedanib

What ifWhat if a pulmonary fibrosis research regimen pairs a MetAP2 inhibitor with pirfenidone and contains no nintedanib?
Claim language“and nintedanib”

The regimen uses separate dosage forms for fumagillin, a covalent MetAP2 inhibitor, and pirfenidone. Pirfenidone supplies antifibrotic activity through a reduction in fibroblast collagen production.

1.1Nerandomilast replaces nintedanib

What ifWhat if a pulmonary fibrosis research regimen pairs a MetAP2 inhibitor with nerandomilast and contains no nintedanib?
Claim language“and nintedanib”

An oral nerandomilast tablet supplies the antifibrotic component through preferential phosphodiesterase 4B inhibition. A separate fumagillin formulation inhibits MetAP2 by covalently modifying an active-site histidine.

1.1Free base replaces nintedanib salt

What ifWhat if the combination uses nintedanib free base in a lipid-filled capsule and contains no nintedanib salt?
Claim language“a pharmaceutically acceptable salt thereof”

Medium-chain triglycerides and a nonionic surfactant disperse the free base in the capsule fill. The fill disperses in gastrointestinal fluid and presents the drug for dissolution and absorption.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Combination testing in veterinary lung cultures

A veterinary research assay uses primary canine lung fibroblasts in a collagen gel to measure matrix contraction. The assay applies a MetAP2 inhibitor and nintedanib to the same gel and uses matched gels for vehicle and single-agent controls. Images taken before and after exposure provide gel area measurements, and a parallel viability assay measures cell survival.

Component substitution

Pirfenidone as the antifibrotic partner

Pirfenidone replaces nintedanib as the second active compound in a lung fibroblast assay. Fibroblasts receive a profibrotic stimulus, and the two compounds are dispensed from separate stocks into the same treatment wells. Vehicle and single-agent wells provide comparison groups for collagen deposition and cell viability measurements.

Parameter or scale variation

Six by six concentration matrix

A 384-well plate holds a matrix with six MetAP2 inhibitor levels and six nintedanib levels. Each axis contains a zero-concentration level and five nonzero levels spaced by twofold dilution, and each of the 36 pairs occupies three wells. Equal final solvent content across wells supports comparison of collagen deposition and cell viability across the matrix.

Combination with existing systems

Perfused lung chip for combination testing

A two-channel microfluidic lung chip places alveolar epithelial cells and lung fibroblasts on opposite faces of a porous membrane. A pump circulates medium containing the MetAP2 inhibitor and nintedanib through the fibroblast channel while the epithelial channel maintains an air–liquid interface. Fluorescent collagen staining measures matrix deposition, and passage of a fluorescent tracer across the membrane measures barrier permeability.

Aerosol exposure in lung tissue slices

A vibrating-mesh aerosol generator delivers a MetAP2 inhibitor formulation into an exposure chamber above precision-cut lung slices on porous inserts. Medium below the inserts contains nintedanib and supplies the tissue through the membrane. Cell-free collection inserts receive the same aerosol exposure and provide samples for liquid chromatography measurement of deposited inhibitor mass.

Automated or data-driven variant

Automated imaging of fibroblast matrix deposition

A liquid handler dispenses the MetAP2 inhibitor and nintedanib into fibroblast culture wells according to a stored plate map. An automated fluorescence microscope collects collagen and nuclear images at fixed fields in each well. Image analysis software divides background-corrected collagen fluorescence by the number of segmented nuclei and joins each result to the corresponding concentrations.

Specific version of a part

Fumagillin with nintedanib esylate

Fumagillin supplies MetAP2 inhibition through an epoxide that reacts with an active-site histidine. A separate lipid-filled oral capsule supplies nintedanib as its ethanesulfonate salt.

Chloroacetylcarbamate derivative of fumagillol

The O-(N-chloroacetylcarbamoyl) derivative of fumagillol supplies MetAP2 inhibition and retains the reactive epoxide. A separate oral capsule delivers nintedanib esylate in a lipid suspension.

Fumagillin salt in aqueous solution

Fumagillin dicyclohexylammonium salt supplies the MetAP2 inhibitor in a separately prepared aqueous formulation for research use. An oral capsule supplies nintedanib esylate.

Separate oral capsule formulations

A hard capsule carries fumagillin in a dry blend with microcrystalline cellulose. A soft capsule carries nintedanib esylate in a suspension of medium-chain triglycerides and a phospholipid dispersant.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2019/0275033 A1
Published
Sep 12, 2019
Filed
May 31, 2017
Class
A61K 31/496
Document BUS 2019/0365744 A1
Published
Dec 5, 2019
Filed
Jan 16, 2018
Class
A61K 31/496
Claim 1
Document A
Document B
1.1at least one MetAP2 inhibitor, or a pharmaceutically acceptable salt thereof, and nintedanib, or a pharmaceutically acceptable salt thereof, for use in treating pulmonary fibrosis in a subject.
Disclosed is a method for treatment of idiopatic pulmonary fibrosis and progressive fibrosing interstitial lung disease (PF-ILD). In one embodiment, the method of the invention comprises administering nintedanib, or pharmaceutical acceptable salt thereof, and pirfenidone, or a pharmaceutical acceptable salt thereof to a patient in need thereof.
A · US 2019/0275033 A1 · abstract
The composition or kit of any one of embodiments 1 to 3, wherein said multi-tyrosine kinase inhibitor is Nintedanib. 5. A composition or kit of any one of embodiments 1 to 4 for use in the treatment of cancer or idiopathic pulmonary fibrosis in a subject suffering from said cancer or idiopathic pulmonary fibrosis. 6.
B · US 2019/0365744 A1 · ¶ 74

An empty cell means only that no passage was reproduced there.

Statements in these documents
Conventional IPF treatments such as n-acetylcysteine (NAC), corticosteroids, cyclophosphamide, cyclosporine and azathioprine are not approved treatments for IPF, and their efficacy is questionable or even harmful.
A · US 2019/0275033 A1 · ¶ 3
Both INPULSIS trials showed that nintedanib reduced the annual rate of decline in FVC (mL/year) by approximately 50%, consistent with slowing disease progression.
A · US 2019/0275033 A1 · ¶ 3
It further contemplates a composition comprising at least one CXCR4 inhibitor for use in the treatment of cancer or idiopathic pulmonary fibrosis in a subject suffering from said cancer or idiopathic pulmonary fibrosis, wherein the subject is receiving a multi-tyrosine kinase inhibitor therapy.
B · US 2019/0365744 A1 · ¶ 3
However, Nintedanib therapy is accompanied by side effects for the patient and its efficacy may be still improved.
B · US 2019/0365744 A1 · ¶ 7
Cite aspatent.fyi, US 2026/0355144 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355144/, SHA-256 284cebd7244e3c78bf2ee78484a6c3c7db2613ffe48b62c697a6c57628555c51
First published
Permanent addresshttps://patent.fyi/US20260355144/
Content fingerprint (SHA-256)284cebd7244e3c78bf2ee78484a6c3c7db2613ffe48b62c697a6c57628555c51
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi